Prognostic value of beta-blocker doses in patients with ventricular tachyarrhythmias

• Verfasst von: Schupp, Tobias [VerfasserIn]
• Verfasst von: Ziyadova, Sevil [VerfasserIn]
• Verfasst von: Reinhardt, Julius [VerfasserIn]
• Verfasst von: Sag, Yusuf Ugur [VerfasserIn]
• Verfasst von: Zworowsky, Max von [VerfasserIn]
• Verfasst von: Reiser, Linda [VerfasserIn]
• Verfasst von: Abumayyaleh, Mohammad S. A. [VerfasserIn]
• Verfasst von: Weidner, Kathrin [VerfasserIn]
• Verfasst von: Saleh, Ahmad [VerfasserIn]
• Verfasst von: Mashayekhi, Kambis [VerfasserIn]
• Verfasst von: Bertsch, Thomas [VerfasserIn]
• Verfasst von: Abba, Mohammed L. [VerfasserIn]
• Verfasst von: Akın, Ibrahim [VerfasserIn]
• Verfasst von: Behnes, Michael [VerfasserIn]
• Titel: Prognostic value of beta-blocker doses in patients with ventricular tachyarrhythmias
• Verf.angabe: Tobias Schupp, Sevil Ziyadova, Julius Reinhardt, Yusuf Ugur Sag, Max von Zworowsky, Linda Reiser, Mohammad Abumayyaleh, Kathrin Weidner, Ahmad Saleh, Kambis Mashayekhi, Thomas Bertsch, Mohammed L. Abba, Ibrahim Akin, Michael Behnes
• E-Jahr: 2022
• Jahr: 24 January 2022
• Umfang: 11 S.
• Fussnoten: Gesehen am 19.12.2023
• Titel Quelle: Enthalten in: Heart and vessels
• Ort Quelle: Tokyo : Springer, 1985
• Jahr Quelle: 2022
• Band/Heft Quelle: 37(2022), 7 vom: Juli, Seite 1213-1223
• ISSN Quelle: 1615-2573
• DOI: doi:10.1007/s00380-021-02018-3
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Beta-blockers
• Sach-SW: Medical treatment
• Sach-SW: Mortality
• Sach-SW: Pharmacological drugs
• Sach-SW: Target dose
• Sach-SW: Ventricular fibrillation
• Sach-SW: Ventricular tachycardia
• K10plus-PPN: 1876352566

Abstract

The study investigates the prognostic significance of beta-blocker (BB) dose in patients with ventricular tachyarrhythmias. Limited data regarding the prognostic impact of BB dose in ventricular tachyarrhythmias is available. A large retrospective registry was used including consecutive patients on BB treatment with episodes of ventricular tachycardia (VT) or fibrillation (VF) from 2002 to 2015. Discharge BB doses were grouped as > 0-12.5%, > 12.5-25%, > 25-50%, and > 50% according to doses used in randomized trials. The primary endpoint was all-cause mortality at three years. Secondary endpoints comprised of a composite arrhythmic endpoint (i.e., recurrences of ventricular tachyarrhythmias and appropriate ICD therapies) and cardiac rehospitalization. Kaplan-Meier survival curves and multivariable Cox regression analyses were applied for statistics. A total of 1313 patients with BB were included; most patients were discharged with > 25-50% of BB target dose (59%). At three years, > 12.5-25% of BB target dose was associated with improved long-term mortality as compared to the > 0-12.5% group (HR = 0.489; 95% CI 0.297-0.806; p = 0.005), whereas higher BB doses did not improve survival (> 25-50%: HR = 0.849; p = 0.434; > 50%: HR = 0.735; p = 0.285). In contrast, the composite endpoint and risk of rehospitalization were not affected by BB target dose. In conclusion, > 12.5-25% of BB target dose is associated with best long-term survival among patients with ventricular tachyarrhythmias. In contrast, risk of the composite arrhythmic endpoint and risk of cardiac rehospitalization were not affected by BB dose.